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Preterm newborns are challenged by an excessive oxidative burden, as a result of several perinatal stimuli, as intrauterine infections,
resuscitation, mechanical ventilation, and postnatal complications, in the presence of immature antioxidant capacities. “Oxygen
radical disease of neonatology” comprises a wide range of conditions sharing a common pathway of pathogenesis and includes
bronchopulmonary dysplasia (BPD) and other main complications of prematurity. Antioxidant strategies may be beneficial in the
prevention and treatment of oxidative stress- (OS-) related lung disease of the preterm newborn. Endotracheal supplementation
or lung-targeted overexpression of superoxide dismutase was proved to reduce lung damage in several models; however, the
supplementation in preterm newborn failed to reduce the risk of BPD, although long-term respiratory outcomes were improved.
Also melatonin administration to small cohorts of preterm newborns suggested beneficial effects on lung OS. The possibility to
identify single nucleotide polymorphism affecting the risk of BPD may help to identify specific populations with particularly high
risk of OS-related diseases and may pose the basis for individually targeted treatments. Finally, surfactant replacement may lead to
local anti-inflammatory and antioxidant effects, thanks to specific enzymatic and nonenzymatic antioxidants naturally present in
animal surfactants.
1. Introduction
Oxidative stress (OS) plays a pivotal role in the pathogenesis
of several pathologic conditions of the preterm newborn,
which are commonly referred to as “oxygen radical diseases
of neonatology” [1]. In fact, the main complications of
prematurity are located within the wide spectrum of OS-
related injury, where bronchopulmonary dysplasia (BPD),
retinopathy of prematurity, intraventricular hemorrhage, and
periventricular leukomalacia are recognized as organ-specific
manifestations [2, 3].
Preterm newborns are subjected to several events leading
to increased reactive oxygen species (ROS) production, as
hyperoxia, mechanical ventilation, and inflammatory and
infective complications [2–5]. Resuscitation of preterm new-
borns with a low oxygen strategy providing FiO
2
<0.3 sig-
nificantly reduces the need for respiratory support and the
incidence of BPD andOSmarkers [6]while a positive relation
was demonstrated between cord levels of total hydroperox-
ides, advanced oxidation protein products, and non-protein-
bound iron and the risk OS-related diseases of prematurity,
including BPD [4]. As in the latest years resuscitation of
term newborns with low FiO
2
was associated with improved
outcome [7] initial FiO
2
of 0.21 is recommended at present
by ILCOR guidelines [8] and stepwise titration of FiO
2
basing on early SpO
2
assessment in the delivery room is
advised for preterm newborns [9–12]. Mechanical ventilation
subsequently triggers inflammation pathways and remod-
eling processes in the developing lung [3, 13]. Therefore,
very early activation of oxidative pathways in the preterm
newborn may significantly affect long-term respiratory out-
comes, indicating urgent need for specific counterbalance
measures.
Antioxidant capacities are inadequate to the elevated
oxidative burden in preterm newborns, both because of
placental-fetal transfer interruption of antioxidant molecules
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2014, Article ID 721043, 10 pages
http://dx.doi.org/10.1155/2014/721043
2 Oxidative Medicine and Cellular Longevity
and insufficient endogenous production [5, 14]. In fact,
fetal levels of antioxidant enzymes (AOEs) as superoxide
dismutase (SOD), catalase (CAT), glutathione peroxidase
(GPx), and reductase (GRx) progressively increase during
gestation, paralleling the maturation of surfactant system
and preterm animal models fail to induce SOD and GPx in
response to oxidative challenges [15, 16], in contrast to term
newborns, who were demonstrated to induce AOEs in case of
fetal distress [17] or resuscitation with high FiO
2
[18].
Besides hyperoxic challenges, also hypoxia is a well-
known activator of OS pathways in the newborn and ROS
are believed to play a central role in the pathogenesis of
hypoxic-ischemic encephalopathy (HIE) and cerebral palsy
[19, 20]. Higher levels of OS markers were detected in the
central nervous system of term newborns who suffered from
HIE in comparison with nonasphyxiated controls, and a
positive correlation was also established between the levels
of OS markers and the severity of HIE [19]. Significant
accumulation of ROS in the central nervous system was
demonstrated in animal models of perinatal asphyxia fol-
lowed by reoxygenation [21]. Moreover, iron release from
erythrocytes and non-protein-bound iron resulted higher
in asphyxiated newborns compared to normoxic controls
[22] and similar results were obtained in isolated erythro-
cytes subjected to hypoxia-reoxygenation challenge [23, 24]
suggesting a possible contribution of this aspect to ROS
formation and OS damage perpetuation after hypoxic insult
[25]. However, the role of hypoxic events in determining
adverse respiratory outcomes in the preterm newborns has
not been investigated so far.
Indeed, recent lines of evidence suggest that the admin-
istration of drugs exerting definite antioxidant and anti-
inflammatory effects or inhibiting downstream enzymes of
OS pathways is associated with improved outcomes in animal
models of perinatal asphyxia or hypoxia-reoxygenation. Par-
ticularly, sodiumhydrosulfide, doxycycline, and cyclosporine
were demonstrated to improve cardiac function [26–28],
while pyrrolidine dithiocarbamate and cyclosporine were
proved to confer neuroprotection [29, 30].
2. Antioxidant Treatments: State of the Art
The present management of respiratory disease in the
preterm newborn is far from optimal, as massive improve-
ment in the treatment of the acute phase of RDS did not
substantially impact on the incidence of BPD and also the
management of patients with BPD relies on poor evidence
[3, 31]. Several observations suggest beneficial effects of
antioxidant therapies in the prevention of hyperoxia-induced
lung injury, and because OS is well known to play a central
role in the pathogenesis of BPD, it appears reasonable to
consider the potentials of antioxidant strategies in the preven-
tion and treatment of such conditions. However, antioxidant
treatments cannot be at present recommended for such indi-
cations, as data from clinical trials are insufficient; therefore
further researches on this topic are urgently needed in order
to evaluate the clinical potential of antioxidants. The main
results obtained with melatonin and AOEs supplementation
or overexpression are reviewed.
2.1. Melatonin. Melatonin (MT) is a pleiotropic molecule
secreted by the pineal gland as circadian rhythm transducer
and exerts a complex of multiple antioxidant effects through
direct and indirect actions on different pathways [32].MT is a
direct antioxidant as it presents scavenger properties against
ROS, particularly hydroxyl radical, with subsequent forma-
tion of active metabolites which in turn show scavenging
activity [33]. Moreover, MT upregulates the expression of
AOEs, particularly GPx, GRx, SOD, and CAT [32] through
the activation of different intracellular signaling pathways as
those triggered by G-proteins, calcium-calmodulin complex,
and NFkB [32]. In neonatal medicine MT is at present
one of the most promising treatments for hypoxic-ischemic
encephalopathy in addition to hypothermia [34].
In a small cohort of preterm newborns with RDS MT
was proved to reduce the nitrite/nitrate ratio and circulating
levels of oxidative and inflammatory markers which are
typically overexpressed in lung tissues of BPD patients, as IL-
6, IL-8, and TNF-alpha [35]. Moreover MT administration
in 110 preterm newborns with RDS was associated with
significantly lower ventilator parameters and lower circu-
lating levels of IL-6, IL-8, and TNF-alpha in comparison
with untreated controls [36]. Although these studies did not
provide data on long-term respiratory outcomes, MT may
be putatively expected to affect the incidence of BPD in
preterm newborns, as inflammatory cytokines overexpres-
sion and lung recruitment of inflammatory cells are main
steps in the pathologic pathway leading to tissue abnor-
malities typical of BPD [3]. Moreover, the beneficial effects
of MT administration on inflammatory markers in RDS
patients are concordant with the observation that MT also
reduced circulating markers of lipid peroxidation in a small
cohort of newborns diagnosed with sepsis [37]. Interestingly,
significantly lower levels of lipid peroxidation markers were
observed in the MT-treated group in comparison to the
placebo group as early as 1 hour after the first administration
[37], suggesting a very precocious activation of MT-induced
antioxidant pathways, which would be of major importance
in the setting of early postnatal prevention of OS-related
complications.
Encouraging results were also obtained in the mouse
model of BPD [38]. In fact, MT-treated animals showed
reduced lung myeloperoxidase and nitrite/nitrate ratio and
increased GPx, SOD, and CAT activity and a more preserved
lung histopathology, suggesting a possible protective role of
MT during the critical processes of alveolization and lung
architecture development in case of unfavorable conditions,
following preterm birth.
As very few data are available on the use ofMT in preterm
newborns, further researches are definitely needed in order to
investigate the possible contribution of MT to the preventive
strategies of OS and inflammation mediated lung injury.
Promising preliminary results and the favorable safety profile
alongwith high feasibility of administration pose the basis for
future studies on MT in the prevention of BPD.
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Table 1: Exogenous administration of rhSOD to preterm newborns with RDS.
Eligible population Administration details Outcomes Reference
Preterm infants
BW 750–1250 g
<24 hrs of life
(𝑛 = 26)
Route: ET
Dose: 0.5mg/Kg or 5mg/Kg or saline,
within 30mins of surfactant, single dose
Reduced neutrophils chemotactic activity
and albumin in tracheal aspirates in the high
dose treatment group versus low dose or
saline.
[39]
Preterm infants
BW 700–1300 g
<24 hrs of life
(𝑛 = 33)
Route: ET
Dose: 2.5mg/Kg or 5mg/Kg or saline,
within 2 hrs of surfactant, up to 7 doses
Reduced neutrophils chemotactic activity
and albumin in tracheal aspirates in the
treatment groups versus saline.
No difference in BPD.
[40]
Long-term follow up of
preterm infants enrolled in
[39, 40]
(𝑛 = 46)
As in [39, 40]
No difference in neurodevelopmental
disorder or chronic respiratory disorders at
median of 28 months of corrected age.
[41]
Preterm infants
BW 600–1200 g
<24 hrs of life
(𝑛 = 302)
Route: ET
Dose: 5mg/Kg or saline,
within 0.5–4 hrs of surfactant, repeated
every 48 hrs until 28 days
No difference in BPD rate, days of
mechanical ventilation, and oxygen
requirement.
Reduced episodes of wheezing requiring
bronchodilators or steroids in the treatment
groups versus saline at 1-year follow-up.
[42]
BW: birth weight; ET: endotracheal.
2.2. Antioxidant Enzymes Replacement. The rationale of
AOEs replacement therapy in preterm newborn in order to
prevent or attenuate adverse respiratory outcomes is based on
data demonstrating that OS is a key activator of respiratory
disease in the preterm newborn, who lack adequate levels
of AOEs. Results of studies investigating treatment with
AOEs in the respiratory disease of the preterm newborn are
summarized in Table 1, while experiments on animal models
are included in Table 2.
Several studies preliminarily proved that SOD is a crucial
enzyme for a proper respiratory function as in animal and
cellular models the absence of SOD3 activity induces severe
lung injury during hyperoxia, while SOD2 overexpression in
type II alveolar cells is associated with prolonged survival
in hyperoxic environment [52, 53] and SOD3 administration
in animal models was proved to reduce lung injury related
to hyperoxia and mechanical ventilation [44–47]. Moreover,
exogenously administered SOD was proved to be rapidly
incorporated into different lung cell types after endotracheal
administration in animal models [46], suggesting the possi-
bility of a reliable route of administration into the lung.
Endotracheal administration of recombinant human
SOD (rhSOD) has been proved to reduce lung injury in
preterm newborns receiving mechanical ventilation for RDS
[39, 40]. In a cohort of 26 newborns with birth weight<1250 g
who were randomized to receive placebo, low dose, or high
dose rhSODwithin 30 minutes after the first surfactant, SOD
levels in serum, tracheal aspirates, and urine significantly
increased in the treatment group with respect to the placebo
group [39]. The effect of the treatment was dose-dependent,
with peak values of serum SOD at 6 hours, and return to
basal value at 4 days for the high dose group in comparison
with 12 hours and 3 days, respectively, for the low dose
group.Moreover, tracheal aspirates of SOD-treated newborns
showed lower levels of markers of acute lung injury, as
neutrophil chemotactic activity and albumin concentration,
suggesting that endotracheal rhSOD administration would
exert a protective role in the acute phase of RDS. Because
a single administration induced an increase in SOD levels
lasting for a period of time likely inadequate to affect the risk
of BPD, a regimen of repeated endotracheal administration
of SOD was subsequently studied [40]. A cohort of 36
preterm newborn with birth weight <1300 g was randomized
to receive placebo, low or high dose of endotracheal rhSOD
within 2 hours of surfactant treatment and every 48 hours as
long as mechanical ventilation was necessary, up to 7 doses.
This strategy induced a 4- to 7-fold increase of SOD activity,
in serum, urine, and tracheal aspirates which persisted over
the 14-day study period. Despite a more prolonged anti-
inflammatory effect obtained with repeated doses than with
a single dose regimen, no differences in the rate of BPD
were detected [40]. A larger trial including 302 preterm
infants with birth weight <1200 g who received rhSOD or
placebo with similar administration schedule showed lower
occurrence of wheezing episodes requiring bronchodilators
or corticosteroids during the first year of life in rhSOD-
treated newborns [42], suggesting that very early reduction
of oxidative lung injury may impact on long-term respiratory
outcomes. Moreover, the subgroup of rhSOD-treated infants
born before 27 weeks of gestational age experienced the
more evident beneficial effect, as they presented a 55%
reduction inwheezing episodes, a 55%decrease in emergency
department accesses, and a 44% reduction in hospitalization
when compared to the group of gestational age matched
untreated infants [42]. However, no difference in the rate
of BPD occurrence was detected [42]. RhSOD was well
tolerated in all treated newborns [39–41].The failure of endo-
tracheal rhSOD treatment to reduce the rate of BPD suggests
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Table 2: Exogenous administration of SOD/CAT or SOD overexpression in animal models of hyperoxic lung injury (modified from [43]).
Models Administration or technique details Outcomes Reference
Rats, hyperoxic
Formulation: liposome-encapsulated
bovine SOD and CAT
Route: IV
Timing: before and during exposure
Increased survival rate and reduced pleural
effusion in the treatment group versus saline [44]
Rats, hyperoxic
Formulation: liposome-encapsulated
bovine SOD and CAT
Route: ET
Timing: before exposure
Increased survival rate and preserved lung
histology in the treatment group versus
controls.
[45]
Piglets, hyperventilated
and hyperoxic
Formulation: rhSOD
Route: ET
Timing: at start of exposure
Reduced neutrophils chemotactic activity,
total cell count, elastase activity, and
albumin in tracheal aspirates versus
controls.
[46]
Rabbits, lung tissue
challenged with xanthine
and xanthine oxidase
Formulation: liposome-encapsulated
bovine SOD and CAT
Route: ET
Preserved lung filtration coefficient in
treated animals versus controls. [47]
Transgenic mice,
hyperoxic Lung-targeted SOD3 overexpression
Reduced lung neutrophils and oxidized
GSH, increased alveolar surface and lung
volume density in transgenic animals versus
wild-type controls.
[48]
Transgenic mice,
hyperoxic Lung-targeted SOD3 overexpression
Preserved alveolar and bronchiolar
epithelium proliferation, reduced DNA
damage, and preserved apical protein
expression on type I cells in transgenic
animals versus wild-type controls.
[49]
Rabbit, hyperoxic
Transfection with rhSOD3 containing
plasmid
Route: AER
Increased lung cGMP and decreased lung
NF-kB expression in transfected animals
versus controls.
[50]
Transgenic mice,
hyperoxic
Lung-targeted SOD3 overexpression +
Antileukinate for 7 days
Route: IP
Reduced lung neutrophils, 8-isoprostane,
and oxidized GSH and reduced
myeloperoxidase activity in tracheal
aspirates of treated transgenic animals
versus treated wild type or untreated
transgenic animals.
[51]
IV: intravenous; ET: endotracheal; IP: intraperitoneal; AER: aerosolized.
that a combination treatment with anti-inflammatory agents
might be considered and investigated in the pretermnewborn
in order to assess possible additive effects.
Further studies on the possibility to increase the lung con-
tent of AOEs inmodels of preterm newborns with hyperoxia-
induced lung injury were performed with novel genetic
techniques as lung targeted AOEs overexpression or AOEs
containing-plasmid transfection. Particularly, lung targeted
human SOD3 overexpression was studied in the newborn
mice model of hyperoxia-induced lung injury [48] basing on
the demonstration that SOD3 overexpression reduced lung
adhesion molecules and inflammatory cytokines in adult
models under hyperoxic conditions [54]. After 7 days of
hyperoxia transgenic mice overexpressing SOD3 had lower
inflammatory markers with respect to wild-type animals, as
demonstrated by lower neutrophils in tracheal aspirates and
reduced myeloperoxidase activity in the lung tissue and also
showed lower content of oxidized GSH in lung homogenates.
Moreover, after 21 days of hyperoxia transgenic animals
showed significant preservation of the alveolar surface area
and of the lung volume density in comparison with wild-type
animals, suggesting a beneficial role of SOD3 overexpression
during the crucial phases of lung development and rearrange-
ment after preterm birth. Theoretically, the beneficial effects
of SOD3 overexpression on lung histopathology may be due
not only to the direct effect of ROS scavenging but also to
the production of a discrete amount of hydrogen peroxide,
which is known to be involved in tissue development and
remodeling, as it takes part in apoptosis and cell proliferation
[48].
The protective effects of SOD3 on postnatal lung devel-
opment were further assessed in preterm animal models
with lung targeted overexpression of human SOD3 during
the transition from the saccular to the alveolar stage [49].
While hyperoxic challenge significantly affected alveolar
development in wild-type animals, transgenic mice showed
preserved proliferation of alveolar and bronchiolar epithelial
cells and also presented less DNAdamage and preservation of
specific apical protein expression on alveolar type I cells [49].
In the hyperoxia-induced lung injury, alveolar macro-
phages are involved in the trigger of inflammatory response
through the secretion of proinflammatory mediators, as
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IL-1beta and TNF-alpha, which are responsible for the
recruitment of further inflammatory cells, activating in turn
inflammatory and oxidative cascades [3, 13].Therefore SOD3
overexpression, which inhibits neutrophils influx into the
lung, was recently studied in addition to Antileukinate,
a potent suppressor of neutrophils chemotaxis, in a mice
neonatal model of hyperoxia-induced lung injury [51]. Trans-
genicmicewith lung targeted overexpression of human SOD3
receiving Antileukinate showed lower content of neutrophils
in the lung and of myeloperoxidase in the bronchoalveolar
lavage as well as lower levels of OS markers and increased
alveolar density in comparison with wild-type treated and
transgenic untreated animals, suggesting a synergistic pro-
tection of SOD3 overexpression and Antileukinate on lung
injury [51].
Finally, a plasmid containing human SOD3 was admin-
istered via aerosol to animal models under hyperoxic con-
ditions and induced a significant increase in lung tissue of
NO bioavailability and cGMP accumulation [50], which is
of major importance to prevent further perfusion/ventilation
mismatch in RDS patients. Moreover, SOD3-treated animals
also showed lower lung content of NF-kB, suggesting a possi-
ble protective role of SOD3 on the downstream inflammatory
pathways [50].
2.3. Genomics and Antioxidant Treatments. Individual
genetic characteristics may condition to a considerable
extent the onset and the magnitude of the inflammatory
and immune responses triggered by specific stimuli in
the fetus and in the preterm newborn [55]. Particularly, a
recent model of the pathogenesis of the complications of
prematurity provides that a hyperresponsive phenotype
activating excessive inflammatory cytokines and ROS
production increases the risk of OS-related complications
[55]. Among other factors, unfavorable genetic background
could include specific polymorphisms of inflammatory
mediators and antioxidant enzymes [56, 57]. A single
nucleotide polymorphism (SNP) is a substitution or a
deletion of a single nucleotide from the original DNA
sequence which occurs every 100–300 base pairs and in at
least 1% of the population [58]. Since BPD is characterized by
a variable association of alveolar and vascular developmental
arrest, inflammatory changes and oxidative damage to
the developing lung [2, 3] SNPs of genes involved in such
pathways were themost extensively investigated. Particularly,
SNPs which influence the risk of BPD in preterm newborns
were identified in genes of IL-6 [59], INF-gamma [60],
Toll-like receptors family and related proteins [61], molecules
regulating inflammatory cells recruitment into the lung,
as L-selectin [62] and macrophage migration inhibitory
factor [63], and factors regulating extracellular matrix
remodeling during lung development and repair, as matrix
metalloproteinases [64]. On the contrary, SNPs of TNF-alpha
do not seem to affect the probability of developing BPD [65].
SNPs of AOEs have been poorly investigated so far, but
the assessment of SNPs leading to reduced amount or activity
of AOEs with adverse effects on the respiratory outcomes
could be of major importance in the clinical perspective
of AOEs replacement therapy or treatment with drugs, as
MT, capable of AOEs induction. The observation of SNPs
with deleterious effects on AOEs activity may pose the basis
for specifically targeted therapeutic interventions. The SNP
Val105Ile in the subclass pi of Glutathione-S-transferase,
encoding for a low-activity variant of the enzyme, was
associated with increased risk of BPD in a small population
of preterm newborns [66]. We recently studied 10 SNPs of
SOD1, SOD2, SOD3, and CAT in a cohort of 152 preterm
newborns ≤28 weeks of gestational age and we demonstrated
that SOD3 SNP rs2536512, resulting in reduced enzymatic
activity, showed a trend towards a protective association
with BPD [56, 57]. In the same population haplotype
reconstruction analysis, which investigates possible additive
effects of more SNPs, demonstrated that the risk of RDS
requiring mechanical ventilation was reduced by specific
haplotypes of SOD1, SOD2, SOD3, while the risk of BPD
was increased by a specific haplotype of SOD2, and it was
increased by a single haplotype in SOD3 [56, 57]. Although
data on SNPs effects on proteomics are definitely incom-
plete, it appears reasonable to hypothesize that unfavorable
haplotypes are associated with impaired antioxidant activity,
resulting in increased oxidative damage to the preterm
lung.
The demonstration of the association of specific SNPs of
AOEs with adverse respiratory outcomes and the clarification
of the effect of the SNPs on the activity of the resultant
protein, which is partly unknown as reviewed elsewhere
[43], may theoretically pose the basis for individually tar-
geted AOEs supplementation. Moreover, also MT treatment
could be speculatively expected to exert beneficial effects in
newborns with SNPs leading to impaired activity of AOEs.
The study of MT treatment may be of particular interest
in this subset of newborns in order to assess whether MT
could compensate for the genetically determined antioxidant
deficit. Speculatively, the early antioxidant effects of MT
treatment observed in newbornsmay occur as a consequence
of MT anti-inflammatory and scavenging activities while the
MT-induced overexpression of AOEsmay be amajor point in
determining later effects [37], particularly in case of multiple
dose treatments. However, neither AOEs activity nor the
production of mRNA for AOEs have been investigated in
newborns following MT treatment.
3. Surfactant, an Antioxidant Treatment?
Endotracheal surfactant administrationwas definitely among
the main contributors to the improvement of the outcome
of preterm birth, as it was proved to significantly reduce
mortality, the need for mechanical ventilation, and the
occurrence of air leaks in pretermnewborn.However, there is
increasing evidence that surfactant not only reduces alveolar
surface tension and improves lung mechanics [67], but also
possesses a complex of anti-inflammatory and antioxidant
properties [68–70], which is only partially known and which
may possibly contribute to the beneficial effects in RDS.
In fact, exogenous surfactant contains definite amounts
of enzymatic and nonenzymatic antioxidant molecules, as
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Table 3: Content of AOEs and nonenzymatic antioxidants of natural surfactants.
Poractant Beractant Bovactant Calfactant
Doses
mg of PLs/Kg 200 100 100 100
mL of surfactant/Kg 2.5 4 2.2 2.86
SOD
U/mg of PLs 0.396 0.474 0.027 0.383
U/mL of surfactant 31.7 11.9 1.21 13.4
U/dose per Kg 73.3 47.6 2.6 38.3
CAT
nmol/min/mL of PLs 0.81 2.60 1.58 3.23
nmol/min/mL of surfactant 64.80 65.00 71.10 113.10
U/dose per Kg 149.80 260.00 157.80 323.50
Plasmalogens
mol % of totalPLs 3.8 ± 0.1 1.5 ± 0.2 0.9 ± 0.3 n.a.
PUPLs
mol % of totalPLs 26 ± 1 6 ± 1 11 ± 1 n.a.
PLs: phospholipids, PUPLs: polyunsaturated phospholipids, n.a.: not available.
summarized in Table 3, which would reduce alveolar ROS
accumulation and prevent local activation of OS pathways
and ROS diffusion; moreover, exogenous surfactant also
replaces endogenous surfactant, which is partially impaired
by ROS [70]. Indeed, lower levels of OS markers were found
in tracheal aspirates of surfactant treated preterm neonates
with respect to untreated preterm controls [71].
Natural calf lung surfactant containsmeasurable amounts
of SOD and CAT and demonstrated scavenging activity
againstH
2
O
2
[70] and endotracheal administration of surfac-
tant induced a significant increase of SOD content in alveolar
type II cells, demonstrating the occurrence of enzyme uptake
via liposome during the surfactant recycle process [70]. It was
recently assessed that 4 natural surfactants, Poractant, Berac-
tant, Calfactant, and Bovactant, contain definite amounts
of SOD and CAT [68]. Particularly, Poractant provided the
major amount of SOD per recommended dose and showed
the highest scavenger activity when incubated with H
2
O
2
,
while Calfactant presented the major amount of CAT per
dose [68]. However, the role of AOEs of surfactant in vivo
still remains to be established.
Surfactant was also studied as a possible vehicle for
AOEs to the intracellular space of the alveolar epithelial cells.
Lung epithelial cells incubated with Beractant plus SOD and
CAT showed higher SOD and CAT activity relative to cells
incubated with enzymes or Beractant alone and these data
were also confirmed in vivo [72]. Liposome encapsulation
of SOD and CAT was also studied to enhance intracellular
delivery of AOEs and such method was proved effective
in increasing AOEs activity in the alveolar cells of preterm
animal models of hyperoxia-induced lung injury [73]. In
vitro, the addition of SOD to natural surfactants resulted in
increased scavenger activities [68] and the addition of both
SOD and CAT led to a higher increase in comparison with
SOD or CAT alone [68].
Natural surfactants also contain antioxidants not pos-
sessing direct catalytic activity per se, as plasmalogens and
polyunsaturated phospholipids (PUPLs) [74]. Among natural
surfactants, Poractant showed the highest concentration of
both plasmalogen and PUPLs [67, 74]. Plasmalogens were
recently demonstrated to reduce lipid peroxidation within
cellmembranes [75] and also to exert antioxidant functions in
low density lipoproteins [76]. Moreover, plasmalogens were
shown to cooperate with cholesterol, surfactant protein B
(SP-B) and SP-C for the assembly of surfactant reservoir and
for the proper disposition of dipalmitoylphosphatidylcholine,
and plasmalogens addiction to surfactant in experimental
models led to further reduction of surface tension in compar-
ison to surfactant alone [67, 74]. Instead, PUPLs are hypoth-
esized to work mainly as substrates for lipid peroxidation
in lung surfactant [74]. Interestingly, in tracheal aspirates
collected at birth in preterm infants, the concentration of
both plasmalogens and PUPLs resulted significantly higher in
newborns who subsequently developed BPD in comparison
to non-BPD controls [77].
Finally, thanks to anti-inflammatory and immune-
modulating properties, surfactant indirectly contributes to
lower lung OS. SP-A and SP-D not only serve as collectins,
favoring the clearance of alveolar pathogens [78, 79], but
they also suppress the proinflammatory pathway mediated
by NF-kB [80], inhibit cytokines secretion, and modulate
lymphocytes proliferation [62]. The role of SP-D may be
of particular importance, as lower levels of SP-D were
detected in tracheal aspirates of preterm newborns who
subsequently developed BPD relative to age-matched non-
BPD controls [81]. Furthermore, SP-D modified by reactive
nitrogen species was proved to lose aggregating activity [79],
and a genetic variant of SP-D was recently found to be
overrepresented in RDS patients, relative to nonRDS controls
[82].
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4. Conclusions
OS stress plays a key role in the pathogenesis of respiratory
disease of the preterm newborn, as a consequence of imma-
ture and inadequate antioxidant capacities in the presence
of multiple oxidative stimuli, resulting from preterm birth,
intensive care management, and inflammatory complica-
tions.
Different antioxidant strategies are under development in
order to prevent and treat respiratory diseases of prematurity,
particularly with the scope of BPD prevention, since current
preventive strategies and medical treatment are definitely
suboptimal. MT has been poorly investigated for this indi-
cation as far as now, but encouraging results were obtained
in preterm newborns and animal models, indicating MT-
induced suppression of OS pathways and upregulation of
AOEs. These data suggest that MT may be considered as a
valuable candidate for future researches in this field. Recent
evidence also suggests potential protective effects of AOEs
supplementation or overexpression against OS-induced lung
injury. However, only a minority of available data were
obtained from clinical settings; therefore larger clinical trials
are mandatory in order to clarify therapeutic potentials of
such strategies.
Genetic factors predisposing to OS-related complications
of prematurity are poorly known. SNPs ofAOEswere recently
investigated in this population and specific associations of
SNPs of SOD and CAT were demonstrated to affect the risk
of BPD. Amore extensive assessment of SNPs involved in the
pathogenesis of newborn lung diseases may be particularly
helpful to identify specific populations with particularly high
risk of adverse outcome, who may maximally benefit from
antioxidant therapies and the clarification of the effects of
SNPs on proteomics may pose the basis for an individually-
targeted AOEs supplementation.
Finally, surfactant replacement, a routine treatment for
RDS patients, could exert lung antioxidant effects, as AOEs
and nonenzymatic antioxidants are naturally present in
animal-derived surfactants. However, their role in vivo
remains to be clarified.
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